{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T06:39:09Z","timestamp":1775543949893,"version":"3.50.1"},"reference-count":77,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T00:00:00Z","timestamp":1645228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatitis D virus (HDV) infection is a chronic viral disease of the liver that is still largely considered to be incurable due to lack of effective treatment options. Without treatment, the risk for the development of advanced liver disease, cirrhosis and hepatocellular carcinoma is significantly high. Currently, new therapeutic options are emerging out of ongoing phase 3 clinical trials, promising a new hope of cure for this devastating liver infection. Recently, bulevirtide, a first in its class HDV entry inhibitor, has received conditional authorization of use from the European Medicines Agency (EMA) and was also submitted for approval in the United States. Other novel therapeutic options in clincal trials include interferon lambda, the prenylation inhibitor lonafarnib and nucleic acidic polymers (NAPs). This review describes all recent advances and ongoing changes to the field of HDV therpaeutics.<\/jats:p>","DOI":"10.1111\/jvh.13651","type":"journal-article","created":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T02:03:00Z","timestamp":1644026580000},"page":"240-251","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Chronic hepatitis D\u2014What is changing?"],"prefix":"10.1111","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4078-7173","authenticated-orcid":false,"given":"David","family":"Yardeni","sequence":"first","affiliation":[{"name":"Liver Diseases Branch National Institute of Diabetes &amp; Digestive &amp; Kidney Diseases National Institutes of Health Bethesda Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo","family":"Heller","sequence":"additional","affiliation":[{"name":"Liver Diseases Branch National Institute of Diabetes &amp; Digestive &amp; Kidney Diseases National Institutes of Health Bethesda Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4755-5607","authenticated-orcid":false,"given":"Christopher","family":"Koh","sequence":"additional","affiliation":[{"name":"Liver Diseases Branch National Institute of Diabetes &amp; Digestive &amp; Kidney Diseases National Institutes of Health Bethesda Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,2,19]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.02.031"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-013-0365-x"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13018"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.18.12.997"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.10.6124"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/323508a0"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.052"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2017.05.008"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021576"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2018.03.013"},{"key":"e_1_2_11_12_1","first-page":"1","article-title":"Prevalence and characteristics of hepatitis delta in the United States: an analysis of all\u2010payer claims database","volume":"74","author":"Gish R","year":"2021","journal-title":"Hepatology"},{"key":"e_1_2_11_13_1","first-page":"1","article-title":"Molecular and clinical epidemiology of hepatitis D virus infection in Canada","volume":"74","author":"Osiowy C","year":"2021","journal-title":"Hepatology"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0037-86822012000600007"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02012-08"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20574"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1323626"},{"key":"e_1_2_11_18_1","first-page":"1","article-title":"Low adherence to guidelines recommendation for testing hepatitis D in HBsAg positive patients leads to a high rate of undiagnosis","volume":"74","author":"Palom A","year":"2021","journal-title":"Hepatology"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12217"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28772"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1323624"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.62.2.594-599.1988"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.62.8.2674-2679.1988"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-83-10-2507"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.67.12.7659-7662.1993"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1598578"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.67.6.3281-3287.1993"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/3-540-29802-9_6"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00049"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.61.5.1672-1677.1987"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2007.07.034"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/3-540-29802-9_8"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29574"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy585"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0676.1994.tb00065.x"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00162-9"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02542.x"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199401133300202"},{"issue":"67","key":"e_1_2_11_40_1","first-page":"370","article-title":"Clinical practice guidelines on the management of hepatitis B virus infection","volume":"2017","author":"EASL","year":"2017","journal-title":"J Hepatol"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.03.017"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21325"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912696"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27102"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.05.029"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30663-7"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12788"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16408"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2016.06.002"},{"key":"e_1_2_11_50_1","unstructured":"Hepcludex product information. European Medicines Agency.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hepcludex. Accessed January 30 2022."},{"key":"e_1_2_11_51_1","volume-title":"Gilead submits biologics license application to U.S. food and drug administration for bulevirtide, an investigational treatment for people living with chronic hepatitis delta","author":"Gilead","year":"2021"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.013"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.016"},{"key":"e_1_2_11_54_1","first-page":"1","article-title":"Interim results of a multicenter, open\u2010label phase 2b clinical trial to assess safety and efficacy of myrcludex B in combination with tenofovir in patients with chronic HBV\/HDV co\u2010infection. Oral Abstracts (Abstracts 1\u2013263)","volume":"66","author":"Wedemever H","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_11_55_1","first-page":"S32018","article-title":"Final results of a multicenter, open\u2010label phase 2b clinical trial toassess safety and efficacy of myrcludex B in combination with tenofovir in patients with chronic HBV\/HDV co\u2010infection","volume":"68","author":"Wedemeyer H","year":"2018","journal-title":"J Hepatol"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30141-0"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)30651-6"},{"key":"e_1_2_11_58_1","first-page":"S291","article-title":"Safety and efficacy of bulevirtide monotherapy and in combination with peginterferon alfa\u20102a in patients with chronic hepatitis delta: 24 weeks interim data of MYR204 Phase 2b study","volume":"75","author":"Asselah TAS","year":"2021","journal-title":"J Hepatol"},{"key":"e_1_2_11_59_1","first-page":"S294","article-title":"Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the phase 3 MYR301 study","volume":"75","author":"Wedemever H","year":"2021","journal-title":"J Hepatol"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2015.10.021"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.12.018"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-016-2920-z"},{"key":"e_1_2_11_63_1","unstructured":"EtzionO DuehrenS&HamidSSet al. Characterization of HDV HBsAg and ALT kinetics under peginterferon\u2010lambda monotherapy: the phase 2 LIMT study. Hepatology 2019;70 1477A\u20101501A"},{"key":"e_1_2_11_64_1","unstructured":"Eiger BiopharmaceutricalsPhase 3 LIMIT\u20102 study.https:\/\/www.eigerbio.com\/lambda\u2010hdv\u2010infection accessed on January 30 2022"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.11.9303-9306.1998"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI17704"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00074-2"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29658"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30327-6"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30464-6"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30310-0"},{"key":"e_1_2_11_72_1","doi-asserted-by":"crossref","unstructured":"KohC HercunJ RahmanF et al.A phase 2 study of peginterferon lambda lonafarnib and ritonavir for 24 weeks: end\u2010of\u2010 study results from the LIFT HDV study. Presented at The Liver Meeting.2020.https:\/\/www.eigerbio.com\/lambda-hdv-infection. Accessed January 30 2022.","DOI":"10.1016\/S0168-8278(20)30774-1"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.07.004"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01003-13"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140909"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156667"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30288-1"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1633"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13651","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.13651","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13651","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T08:49:15Z","timestamp":1692953355000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,19]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1111\/jvh.13651"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13651","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,19]]},"assertion":[{"value":"2021-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}